SU2C Catalyst® Research Grant with Support from BMS: Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab - Stand Up To Cancer

Blog

Posted October 10, 2019

SU2C Catalyst® Research Grant with Support from BMS: Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.